Bausch + Lomb (BLCO)

• Market cap: $4.36B
• 1 day: -0.88%
• 5 days: 5.84%
• 1 month: 4.85%
• 3 months: -18.83%
• 6 months: -33.71%
• Year to date: -31.50%
• 1 year: -17.08%
• 5 years: -38.35%
• 10 years: -38.35%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,500

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $11.6M | Put options by funds: $10.7M

0.75% more ownership

Funds ownership: 9.71% [Q4 2024] → 10.46% (+0.75%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 33

5% less funds holding

Funds holding: 112 [Q4 2024] → 106 (-6) [Q1 2025]

13% less capital invested

Capital invested by funds: $618M [Q4 2024] → $535M (-$83.4M) [Q1 2025]

19% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 31

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 3% downside
• Avg. target: $14.44 17% upside
• High target: $17 38% upside

8 analyst ratings

• positive: 3 38%
• neutral: 5 63%
• negative: 0 0%

Barclays Matt Miksic	30% upside $16	Equal-Weight Maintained	9 Jun 2025
Morgan Stanley Patrick Wood	3% downside $12	Equal-Weight Maintained	6 May 2025
HC Wainwright & Co. Yi Chen	22% upside $15	Buy Maintained	2 May 2025
Citigroup Joanne Wuensch	5% upside $13	Neutral Maintained	1 May 2025
Wells Fargo Larry Biegelsen	3% downside $12	Equal-Weight Maintained	1 May 2025